Currently, some genetic and epigenetic alternations such as epidermal growth factor receptor amplification, HER2/neu over expression (49), and c-Kit (CD 117) (50) activating mutation has been considered in thymoma pathogenesis (28). This evidence concerns the gene ERBB2 and thymoma.